US2005084501A1PendingUtilityA1

Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food

58
Priority: Jun 16, 2000Filed: Oct 8, 2004Published: Apr 21, 2005
Est. expiryJun 16, 2020(expired)· nominal 20-yr term from priority
Inventors:Akikuni Yagita
A23L 33/10A61P 35/00A61K 45/06A61K 36/074A61K 31/737A61K 31/702A61K 31/7016A61K 36/07G01N 2500/00G01N 2333/70596G01N 2333/705G01N 33/575
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic agent for a cancer comprising a therapeutically effective amount of an active ingredient, wherein the therapeutic agent is used referring to an ability of acting on NK cell antigen receptor NKR-P1 of NKT cell as an index of the ability to activate the NKT cell.

Claims

exact text as granted — not AI-modified
1 . A therapeutic agent for a cancer comprising a therapeutically effective amount of an active ingredient, wherein the therapeutic agent is used referring to an ability of acting on natural killer receptor P1 of natural killer T cell as an index of the ability to activate the natural killer T cell.  
     
     
         2 - 18 . (canceled)  
     
     
         19 . A method for detecting activation of natural killer T cells comprising assaying natural killer receptor P1 that exists on the cell surface of natural killer T cells.  
     
     
         20 . The method of  claim 19 , wherein said assaying natural killer receptor P1 that exists on the cell surface of natural killer T cells measures CD3 and CD161 cell surface markers.  
     
     
         21 . The method of  claim 20 , wherein said CD3 and CD 161 cell surface markers that are measured are positive CD3 and CD161 cell surface markers.

Join the waitlist — get patent alerts

Track US2005084501A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.